Vaderis Therapeutics
Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia
$152MSeries B
Role not disclosedLoading investors…
Activity from announced rounds
Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia
Develops treatments for chronic lung diseases, focusing on viral respiratory infections